Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Large Cap
  • M&A
  • Markets
  • Movers
  • News
  • Small Cap

AstraZeneca To Acquire US Respiratory Vaccine Player Icosavax For Over $800M

By Vandana Singh
December 12, 6:55 AM
AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Icosavax Inc (NASDAQ: ICVX) at $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable up

AZN

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Equities
  • General
  • Health Care
  • Markets
  • Movers
  • News
  • Price Target
  • Reiteration
  • Trading Ideas

Blood Cancer Player Arcellx’s Lead Product Exceeds Expectations, Analysts Say

By Vandana Singh
December 11, 3:33 PM
Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or 

ACLX

Read More
1 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Markets
  • Movers
  • News
  • Small Cap

What’s Going On With Leukemia-Focused Syndax Pharmaceuticals Stock Today?

By Vandana Singh
December 11, 2:47 PM
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) shares are trading higher after the company shared data from multiple trials of revumenib in combination with standard-of-care agents in patients with nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2r) relapsed/refractory 

SNDX

Read More
1 minute read
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks

Once High-Flying Direct-To-Consumer Dentistry Company SmileDirectClub Shuts Down

By Vandana Singh
December 11, 2:00 PM
SmileDirectClub Inc (OTC: SDCCQ) shut down after filing for bankruptcy in the U.S. in September.

SDCCQ

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Legal
  • News

Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions

By Vandana Singh
December 11, 1:11 PM
Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion in 

GILD

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

Eli Lilly Stock Is Tumbling Today – Here’s Why

By Vandana Singh
December 11, 1:02 PM
Eli Lilly And Co (NYSE: LLY) announced the detailed results from the SURMOUNT-4 Phase 3 study evaluating the safety and efficacy of Zepbound (tirzepatide) compared to a placebo for obesity with weight-related comorbidities, 

LLY

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Cogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatment

By Vandana Singh
December 11, 12:37 PM
Cogent Biosciences Inc (NASDAQ: COGT) shared data from Part 1 of its ongoing Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) at the American Society of Hematology

COGT

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Why Is Cancer Focused Poseida Therapeutics Stock Trading Higher Today?

By Vandana Singh
December 11, 12:17 PM
Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor 

PSTX

Read More
1 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Markets
  • Movers
  • News
  • Penny Stocks

Acurx’s Antibiotic Shows All Patients With Clinical Cure Remained Infection-Free After End Of Treatment

By Vandana Singh
December 11, 11:50 AM
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) released Phase 2b results showing 100% of C.

ACXP

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today – Here’s Why

By Vandana Singh
December 11, 10:05 AM
Pasithea Therapeutics Corp (NASDAQ: KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 in NRAS mutation 

AZN

Posts pagination

Previous 1 … 100 101 102 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service